Taofeek Owonikoko, MD Discusses lurbinectedin as a Potential Practice Changing in SCLC Treatment

Lurbinectedin, a potential practice changing drug if approved, will be the only agent available in SCLC tested with immunotherapy. PharmaMar to submit New Drug Application (NDA) for lurbinectedin unde... Author: PharmaMar Added: 08/21/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts